home / stock / coll / coll news


COLL News and Press, Collegium Pharmaceutical Inc. From 05/09/24

Stock Information

Company Name: Collegium Pharmaceutical Inc.
Stock Symbol: COLL
Market: NASDAQ
Website: collegiumpharma.com

Menu

COLL COLL Quote COLL Short COLL News COLL Articles COLL Message Board
Get COLL Alerts

News, Short Squeeze, Breakout and More Instantly...

COLL - Collegium Announces CEO Transition

– Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has Initiated the Search for a Successor – S...

COLL - Expected US Company Earnings on Thursday, May 9th, 2024

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

COLL - Collegium enters authorized generic agreement with Hikma for Nucynta franchise

2024-04-29 10:13:02 ET More on Collegium Pharmaceutical Collegium Pharmaceutical Q4: The Beat Goes On Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript Collegium Pharmaceutical, Inc. 2023 Q4 - Results - Earnings Call Presentation Collegium Ph...

COLL - Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER

STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced it has entered into an authorized generic ...

COLL - Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024...

COLL - Collegium Pharmaceutical to redeem outstanding 2.625% convertible senior notes due 2026

2024-04-11 08:53:21 ET More on Collegium Pharmaceutical Collegium Pharmaceutical Q4: The Beat Goes On Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript Collegium Pharmaceutical, Inc. 2023 Q4 - Results - Earnings Call Presentation Collegium Ph...

COLL - Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has ...

COLL - Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference

STOUGHTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a ...

COLL - Trading (COLL) With Integrated Risk Controls

2024-03-21 14:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

COLL - IXJ: Healthcare Sector Dashboard For March

2024-03-18 14:07:39 ET Summary The healthcare sector is overvalued by about 13% relative to 11-year averages, but overvaluation varies a lot across subsectors. Healthcare equipment has the worst value and quality scores. iShares Global Healthcare ETF is a global alternative to...

Previous 10 Next 10